Diamedica Therapeutics Stock Today
| DMAC Stock | USD 4.70 0.52 12.44% |
Performance6 of 100
| Odds Of DistressLess than 38
|
DiaMedica Therapeutics is trading at 4.70 as of the 24th of November 2024, a 12.44 percent increase since the beginning of the trading day. The stock's open price was 4.18. DiaMedica Therapeutics has about a 38 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for DiaMedica Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 4th of May 2023 and ending today, the 24th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 4th of January 2008 | Category Healthcare | Classification Health Care |
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota. Diamedica Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 42.76 M outstanding shares of which 175.55 K shares are currently shorted by private and institutional investors with about 3.88 trading days to cover. More on DiaMedica Therapeutics
Moving against DiaMedica Stock
DiaMedica Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Dietrich MBA | |||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Pharmaceutical Products (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsDiaMedica Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand DiaMedica Therapeutics' financial leverage. It provides some insight into what part of DiaMedica Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
DiaMedica Therapeutics (DMAC) is traded on NASDAQ Exchange in USA. It is located in 301 Carlson Parkway, Minneapolis, MN, United States, 55305 and employs 18 people. DiaMedica Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 200.97 M. DiaMedica Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 42.76 M outstanding shares of which 175.55 K shares are currently shorted by private and institutional investors with about 3.88 trading days to cover.
DiaMedica Therapeutics currently holds about 38.44 M in cash with (18.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.45.
Check DiaMedica Therapeutics Probability Of Bankruptcy
Ownership AllocationDiaMedica Therapeutics holds a total of 42.76 Million outstanding shares. DiaMedica Therapeutics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check DiaMedica Ownership Details
DiaMedica Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Ronald Blue Trust, Inc. | 2024-09-30 | 44.2 K | |
| Susquehanna International Group, Llp | 2024-06-30 | 43.4 K | |
| Catalyst Financial Partners Llc | 2024-09-30 | 38.5 K | |
| Lpl Financial Corp | 2024-06-30 | 17.5 K | |
| Stonebridge Capital Advisors Llc | 2024-09-30 | 17.5 K | |
| Dimensional Fund Advisors, Inc. | 2024-09-30 | 17 K | |
| Bnp Paribas Arbitrage, Sa | 2024-06-30 | 15.2 K | |
| Jane Street Group Llc | 2024-06-30 | 15.1 K | |
| Charles Schwab Investment Management Inc | 2024-09-30 | 13.3 K | |
| Cooperman Leon G | 2024-09-30 | 1.5 M | |
| Vanguard Group Inc | 2024-09-30 | 1 M |
DiaMedica Therapeutics Historical Income Statement
DiaMedica Stock Against Markets
DiaMedica Therapeutics Corporate Management
| MS MD | Independent Consultant | Profile | |
| Scott CA | CFO Sec | Profile | |
| Edward Calamai | Consulting Manufacturing | Profile | |
| Ambarish Shah | Chief Officer | Profile | |
| Lorianne MD | Chief Officer | Profile | |
| Julie CCRP | Senior Operations | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DiaMedica Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DiaMedica Therapeutics. If investors know DiaMedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DiaMedica Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.56) | Return On Assets (0.24) | Return On Equity (0.35) |
The market value of DiaMedica Therapeutics is measured differently than its book value, which is the value of DiaMedica that is recorded on the company's balance sheet. Investors also form their own opinion of DiaMedica Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is DiaMedica Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DiaMedica Therapeutics' market value can be influenced by many factors that don't directly affect DiaMedica Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DiaMedica Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if DiaMedica Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DiaMedica Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.